Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

6.710
+0.2904.52%
Volume:24.83M
Turnover:169.96M
Market Cap:4.17B
PE:49.13
High:7.330
Open:6.480
Low:6.400
Close:6.420
52wk High:25.000
52wk Low:6.200
Shares:622.00M
HK Float Shares:622.33M
Volume Ratio:9.19
T/O Rate:3.99%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.137
ROE:1.87%
ROA:1.33%
PB:1.82
PE(LYR):49.13
PS:4.88

Loading ...

Shandong Boan Biotechnology (06955) Releases Monthly Return for November 2025

Bulletin Express
·
Dec 03, 2025

BOAN BIOTECH (06955) Rises Nearly 7% in Early Trading as Aflibercept Ophthalmic Injection Solution Gains NMPA Approval

Stock News
·
Nov 27, 2025

BRIEF-Shandong Boan Biotechnology Says Boyoujing Approved For Marketing In China By NMPA

Reuters
·
Nov 26, 2025

BOAN BIOTECH (06955): Aflibercept Ophthalmic Injection Solution Boyoujing® Approved for Launch in China

Stock News
·
Nov 26, 2025

Shandong Boan Biotechnology Wins China Approval for Boyoujing Aflibercept Injection

Reuters
·
Nov 26, 2025

Shandong Boan Biotechnology - Boyoujing Approved for Marketing in China by Nmpa

THOMSON REUTERS
·
Nov 26, 2025

Ocumension Therapeutics Receives NMPA Approval to Market OT-702 in China

Reuters
·
Nov 26, 2025

Luye Pharma Unit to Raise $150 Million via Boan-Linked Exchangeable Shares

MT Newswires Live
·
Nov 21, 2025

HK Stock Connect Shareholding Changes | November 12

Stock News
·
Nov 12, 2025

BOAN BIOTECH (06955) Rises Over 4% in Afternoon Trading as Two Denosumab Injections Receive MHRA Approval in UK

Stock News
·
Nov 10, 2025

Shandong Boan Biotechnology (6955) Gains UK Acceptance for Two Denosumab Injections

Bulletin Express
·
Nov 07, 2025

BOAN BIOTECH (06955): UK Marketing Authorization Applications for Two Denosumab Injections Accepted

Stock News
·
Nov 07, 2025

UK MHRA Accepts Shandong Boan’s Marketing Applications for Two Denosumab Injections

Reuters
·
Nov 07, 2025

Shandong Boan Biotechnology - Marketing Authorisation Applications for Two Denosumab Injections Accepted in UK

THOMSON REUTERS
·
Nov 07, 2025

Shandong Boan Biotechnology (06955) Announces No Change in Share Capital for October 2025

Bulletin Express
·
Nov 05, 2025

Shandong Boan Biotechnology (6955) Completes Phase III Patient Enrollment for Nivolumab Injection

Bulletin Express
·
Oct 31, 2025

BOAN BIOTECH (06955) Completes Patient Enrollment for Phase III Clinical Trial of Nivolumab in China

Stock News
·
Oct 30, 2025

Shandong Boan Completes Phase III Trial Enrollment for Nivolumab Biosimilar in China

Reuters
·
Oct 30, 2025

HK Movers | HK's Biotech Shares Soar. Xuanzhu Bio up 19%; TransThera up 13%

Tiger Newspress
·
Oct 22, 2025

Impact of Bulk Procurement on Commercial Logic: Can BOAN BIOTECH (06955) Recover After a 30% Stock Decline Over Two Months?

Stock News
·
Oct 17, 2025